TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients
A new update from the PARTNER 2A trial shows transcatheter aortic valve replacement with Edwards Lifesciences' Sapien XT yields similar outcomes to valve surgery in intermediate risk patients.
